Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / LLY
Stock rating · Pharmaceutical Preparations
Eli Lilly & Co. (LLY) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Eli Lilly & Co. 71 out of 100 (Highest Conviction). Its highest factor score is earnings track record at 92, and its lowest is valuation at 33.
MELANY ratingRated 2026-10-07LLY · composite score
About Eli Lilly & Co.
Eli Lilly is a drug firm focused on neuroscience, cardiometabolic disease, cancer, and immunology. Its key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions; and Taltz and Olumiant for immunology.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How LLY's rating has moved
- +2Past week, since Sep 30: score rose 2 points to 71.
- +4Past four weeks, since Sep 9: score rose 4 points to 71.
Weekly points: Sep 9: 67 · Sep 16: 69 · Sep 23: 70 · Sep 30: 69 · Oct 7: 71 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why LLY scores 71/100
LLY's 8 factor scores run from 33 to 92, and 5 of them sit above its composite of 71. Here is how LLY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 24.6x, earnings growth accelerating
- PEG ratio 1.13 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 83%
- ROE 102%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +25%
- Earnings in 22 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Institutional net buying +10.7%
Near-term events that could move the stock.
- Earnings in 22 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How LLY compares
As of October 7, 2026, Eli Lilly & Co. ranks 5th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Also ranked in Healthcare Stocks. All stock rating pages.
Key risks for LLY
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Eli Lilly & Co. sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 61/100 for strength. Theme strength feeds LLY's momentum and catalyst factors above.
LLY trade plan (Pro)
MELANY has a full position plan for Eli Lilly & Co.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates LLY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Eli Lilly & Co.'s 71/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about LLY
Is Eli Lilly & Co. (LLY) a buy?
As of 2026-10-07, MELANY rated Eli Lilly & Co. Highest Conviction with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Eli Lilly & Co.'s MELANY score?
Eli Lilly & Co. (LLY) has a MELANY composite score of 71/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the LLY stock rating calculated?
MELANY scores LLY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Eli Lilly & Co. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Eli Lilly & Co. (LLY) Highest Conviction with a composite of 71/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the LLY stock price forecast?
MELANY does not publish price targets or forecasts for LLY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for Eli Lilly & Co., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is LLY stock overvalued or undervalued?
MELANY's valuation factor currently reads 33/100 for Eli Lilly & Co., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives LLY's read.
What price should I buy LLY at?
Rather than chasing the current price, MELANY computes a smart entry zone for LLY: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying LLY stock?
The top risks MELANY currently flags for Eli Lilly & Co.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Eli Lilly & Co. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 86/100 for Eli Lilly & Co., and earnings track record, at 92/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will LLY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 62/100 for LLY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this LLY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores LLY continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, LLY included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.